Eric Halioua – President & CEO, PDC*line Pharma
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Address: Rue de Stallestraat 63/4, B-1180 Brussels,Belgium
Tel:
Web: http://www.octapharma.com/en.html
Our Group-wide mission is the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our Mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins. We respect human plasma as a sparce resource for life saving therapies.
The Octapharma portfolio focuses on protein and other biopharmaceutical products derived from human plasma, in three therapeutic areas:
Haematology
Coagulation factors to treat bleeding disorders.
Intensive Care and Emergency Medicine
Plasma and blood proteins (such as albumin) used to stabilise blood circulation, restore coagulation function, and prevent shock, e.g., for heavy burns, injuries, and in surgery.
Immunotherapy
Immunoglobulins to treat immune disorders and prevent rhesus incompatibility in pregnancies.
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
See our Cookie Privacy Policy Here